Parnell Pharmaceuticals announced that it has developed what will be the first antiviral nasal spray in the United States. Nomovid™ Nasal Spray will be easy-to-use, low-cost and can be quickly made available over-the-counter for consumers. Nomovid is based upon a substance licensed by Parnell from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Parnell had been taking the necessary steps to enter the FDA approval process for the MRSA indication until it reportedly saw very positive results against COVID-19. The company is now filing for the COVID-19 indication instead. The company has submitted a White Paper to the U.S. government program Operation Warp Speed, seeking funding and an Emergency Use Authorization, which will allow the product to be manufactured and distributed while doing the necessary Phase III Clinical Trials.